RecruitingPhase 2NCT07117851
A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease
Studying Extramammary Paget disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fudan University
- Intervention
- Disitamab Vedotin combined with Bicalutamide(drug)
- Enrollment
- 20 target
- Eligibility
- 18 years · MALE
- Timeline
- 2025 – 2027
Study locations (1)
- Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
Collaborators
Fujian Province Tumor Hospital · Qinghai Province Cancer Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07117851 on ClinicalTrials.govOther trials for Extramammary Paget disease
Additional recruiting or active studies for the same condition.